TRV GP VI, LLC

TRV GP VI, LLC is an institutional investment manager affiliated with Third Rock Ventures, a biotechnology-focused venture capital firm headquartered in Boston, Massachusetts. The entity functions as a general partner vehicle for one of the Third Rock Ventures funds, and it files Form 13F with the U.S. Securities and Exchange Commission under CIK 0001990716. Third Rock Ventures is known for founding, incubating, and scaling early-stage life sciences companies, with a primary focus on biotechnology and therapeutics. TRV GP VI, LLC represents the public-equity interface of this activity: its 13F reports typically capture positions in portfolio companies that have progressed from private venture-backed status to being publicly listed, as well as any additional public biotech or life sciences exposures held within the fund structure. As a Form 13F filer, TRV GP VI, LLC is recognized by the SEC as an institutional investment manager with discretionary authority over reportable U.S.-listed securities. Each quarterly Form 13F filed under CIK 0001990716 discloses long positions in individual issuers, share counts, and quarter-end market values, providing a standardized, regulator-defined snapshot of the fund’s public biotech and related holdings. Within a 13F analytics context, the complete 13F History for TRV GP VI, LLC can be organized chronologically to trace how its public holdings in specific life sciences names evolve over time—through IPOs, follow-on offerings, and subsequent monetization events. This record forms the empirical basis for allocator analysis, separate from marketing narratives about the broader Third Rock Ventures platform.

TRV GP VI, LLC’s investment activity, as reflected in its 13F filings, is an extension of Third Rock Ventures’ core strategy of company creation in the life sciences sector. Third Rock typically partners with scientific founders to form biotechnology companies focused on novel therapeutics, platform technologies, or other high-science healthcare innovations. The GP entity’s public-equity portfolio therefore consists largely of stakes in these companies once they have listed on public markets. Key characteristics of the strategy implied by the 13F data include: - Sector specialization: The portfolio is overwhelmingly concentrated in healthcare, and within that, in biotechnology and life sciences issuers. These are often development-stage or early commercial-stage companies with significant R&D intensity and binary clinical or regulatory catalysts. - Growth orientation: Underlying holdings tend to be high-growth or pre-revenue enterprises where value is driven by intellectual property, drug pipelines, and scientific risk-reward rather than traditional earnings or dividend metrics. The style is inherently growth and innovation focused. - Concentration: Venture-backed GP entities such as TRV GP VI, LLC typically hold relatively few public positions at any one time, with large percentage stakes in a handful of portfolio companies that have completed IPOs. That creates a concentrated book where a small number of names dominate exposure. - Long investment horizon: Positions often originate from early private investments and persist through IPO and secondary offerings. As a result, effective holding periods are long, with turnover driven mainly by liquidity events, staged monetization, or strategic exits rather than tactical trading. By examining the evolution of TRV GP VI, LLC’s 13F Portfolio Composition—including the number of line items, the weight of top holdings, and the entry and exit of specific biotech names—allocators can infer how the fund manages public exposure throughout the lifecycle of its portfolio companies. The strong linkage between the 13F portfolio and the underlying venture pipeline differentiates this manager from diversified public-equity funds. Using holdings-based tools such as a Backtesting Service or Portfolio Simulator, the quarter-end positions disclosed by TRV GP VI, LLC can be converted into a synthetic equity curve for the public sleeve. Normalized to a chosen starting notional, this historical replication allows construction of an implied Historical Track Record for the manager’s long, listed biotech exposures, which can then be compared to biotech indices or broader equity benchmarks.

TRV GP VI, LLC, filing under SEC CIK 0001990716, is the public-equity-facing GP entity for a Third Rock Ventures fund, providing a focused window into the firm’s biotechnology and life sciences investments once they reach public markets. The 13F filings reveal a concentrated, growth-oriented equity book centered on a limited number of venture-backed biotech issuers, reflecting Third Rock’s company-creation model and long-horizon approach. Using the 13F record, allocators can reconstruct a holdings-based Historical Track Record for TRV GP VI, LLC’s disclosed long exposures, analyze the structure and evolution of its 13F Portfolio Composition, and quantify downside experiences through measures such as Max Drawdown Depth. Overlaying risk-adjusted diagnostics like Sharpe Ratio provides an integrated view of how the volatility inherent in concentrated biotech investing has translated into historical risk-adjusted outcomes for the public sleeve. With these building blocks, Performance Backtests Online and a Portfolio Simulator can be used to explore how TRV GP VI, LLC’s 13F-implied capital path would have behaved under different benchmarks (broad equity vs. biotech-specific), start dates, and market environments, while holding the actual disclosed trading history fixed. The key open question for forward-looking analysis is how sensitive this highly specialized, biotech-centric portfolio will be to future shifts in clinical success rates, regulatory climate, sector funding conditions, and risk appetite compared with the historical regime captured in its existing 13F History.

TRV GP VI, LLC embodies the risk characteristics of concentrated, venture-backed biotechnology investing translated into public markets. The underlying companies are frequently clinical-stage or early commercial-stage issuers whose valuations are highly sensitive to trial results, regulatory decisions, partnering activity, and capital markets conditions. Major elements of the risk profile, observable through the 13F dataset, include: - Idiosyncratic and event risk: Individual holdings can experience large price swings around clinical readouts or FDA actions. With substantial capital in a small number of names, single-stock outcomes can materially drive the overall capital trajectory. - Sector and factor concentration: The public book is heavily tilted toward biotech and life sciences, with high exposure to factors such as small/mid-cap size, high R&D intensity, and high volatility. Correlation to specialized biotech indices is typically higher than to broad market benchmarks. - Liquidity and market-depth risk: Some holdings may be in relatively thinly traded small- or mid-cap biotech stocks. In stress scenarios or during sector-wide drawdowns, liquidity constraints can magnify realized volatility and make staged exits more challenging. Reconstructing TRV GP VI, LLC’s 13F holdings into a time series of hypothetical portfolio values enables explicit measurement of downside characteristics. Metrics such as Max Drawdown Depth, drawdown duration, and recovery patterns help quantify how painful past biotech bear phases or sentiment swings would have been for capital tied to this public sleeve. From the same reconstructed series, risk-adjusted outcome measures like Sharpe Ratio can be computed to evaluate how the variability associated with concentrated biotech exposure has historically translated into cumulative capital growth. Comparing these results to sector indices and to more diversified healthcare managers helps highlight the trade-off between specialization-driven upside potential and elevated volatility. It is important to note that Form 13F only captures the U.S.-listed long positions of the fund. Private holdings in pre-IPO portfolio companies, any derivative hedges, and non-reportable instruments are not visible. For a venture platform like Third Rock Ventures, the 13F lens therefore isolates a specific, but economically meaningful, segment of the overall strategy: the public-market realization phase of its life sciences investments.